Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

NCT06961721 is registered in ClinicalTrials.gov with Changchun BCHT Biotechnology Co. as lead sponsor.

NCT NCT06961721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06961721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
Lead sponsor
Changchun BCHT Biotechnology Co.
Phase
Phase 4
Overall status
Not yet recruiting
Start date
May 31, 2025
Completion date
December 31, 2025
Enrollment
600 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of herpes zoster